Senseonics Holdings, Inc. Announces Executive Appointments
October 06, 2020 at 04:17 pm EDT
Share
On September 30, 2020, the board of directors (the “Board”) of Senseonics Holdings, Inc. (the “Company”) appointed Robert Schumm and Anthony Raab to serve as directors of the Company, which appointments became effective on October 1, 2020. Mr. Schumm will serve as a Class I director whose term will expire at the 2023 annual meeting of stockholders. Mr. Raab will serve as a Class II director whose term will expire at the 2021 annual meeting of stockholders. Robert Schumm, age 54, has served as the President and Chief Executive Officer of Ascensia Diabetes Care AG and has led the Diabetes Management Domain for PHC Group since October 2019. Mr. Schumm has also served as the President of Ascensia Diabetes Care US, Inc. since January 2016. Anthony Raab, age 40, is a co-founder of Masters Special Situations, LLC (“Masters”), and has served as a Senior Analyst at Masters Capital Management since 2015.
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems, Eversense, Eversense XL, and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every five minutes to a mobile app on the user's smartphone. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. Its CGM system continually and accurately measures a person's glucose levels for up to six months.
SENSEONICS HOLDINGS, INC. 
